Jain PharmaBiotech, Basel, Switzerland.
Med Princ Pract. 2017;26(5):399-414. doi: 10.1159/000481403. Epub 2017 Sep 11.
Personalized management of cardiovascular disorders (CVD), also referred to as personalized or precision cardiology in accordance with general principles of personalized medicine, is selection of the best treatment for an individual patient. It involves the integration of various "omics" technologies such as genomics and proteomics as well as other new technologies such as nanobiotechnology. Molecular diagnostics and biomarkers are important for linking diagnosis with therapy and monitoring therapy. Because CVD involve perturbations of large complex biological networks, a systems biology approach to CVD risk stratification may be used for improving risk-estimating algorithms, and modeling of personalized benefit of treatment may be helpful for guiding the choice of intervention. Bioinformatics tools are helpful in analyzing and integrating large amounts of data from various sources. Personalized therapy is considered during drug development, including methods of targeted drug delivery and clinical trials. Individualized recommendations consider multiple factors - genetic as well as epigenetic - for patients' risk of heart disease. Examples of personalized treatment are those of chronic myocardial ischemia, heart failure, and hypertension. Similar approaches can be used for the management of atrial fibrillation and hypercholesterolemia, as well as the use of anticoagulants. Personalized management includes pharmacotherapy, surgery, lifestyle modifications, and combinations thereof. Further progress in understanding the pathomechanism of complex cardiovascular diseases and identification of causative factors at the individual patient level will provide opportunities for the development of personalized cardiology. Application of principles of personalized medicine will improve the care of the patients with CVD.
心血管疾病(CVD)的个体化管理,也称为个体化或精准心脏病学,根据个体化医学的一般原则,是为个体患者选择最佳治疗方法。它涉及整合各种“组学”技术,如基因组学和蛋白质组学,以及其他新技术,如纳米生物技术。分子诊断和生物标志物对于将诊断与治疗联系起来以及监测治疗至关重要。由于 CVD 涉及到大型复杂生物网络的扰动,因此可以采用系统生物学方法进行 CVD 风险分层,以改进风险估计算法,并且对治疗的个体化获益进行建模可能有助于指导干预措施的选择。生物信息学工具有助于分析和整合来自各种来源的大量数据。个体化治疗在药物开发中得到考虑,包括靶向药物递送和临床试验的方法。个体化建议考虑了患者心脏病风险的多个因素——遗传和表观遗传。个体化治疗的例子是慢性心肌缺血、心力衰竭和高血压的治疗。类似的方法可用于心房颤动和高胆固醇血症的管理,以及抗凝剂的使用。个体化管理包括药物治疗、手术、生活方式改变以及它们的组合。对复杂心血管疾病发病机制的进一步深入了解以及在个体患者水平上确定致病因素,将为个体化心脏病学的发展提供机会。个性化医学原则的应用将改善 CVD 患者的护理。